194 related articles for article (PubMed ID: 3496051)
1. [Experimental studies on the treatment of recurrent gliomas].
Yamada M; Shimizu K; Okamoto Y; Miyao Y; Matsui Y; Tsuda N; Mogami H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1890-5. PubMed ID: 3496051
[TBL] [Abstract][Full Text] [Related]
2. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
3. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
4. [Possibility of overcoming of ACNU resistance in an ACNU-resistant subline of C6 rat glioma].
Yoshida T; Shimizu K; Ushio Y; Mogami H; Sakamoto Y
No To Shinkei; 1986 Nov; 38(11):1065-70. PubMed ID: 3468959
[TBL] [Abstract][Full Text] [Related]
5. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism and overcoming of resistance in ACNU-resistant sublines of rat brain tumors].
Yoshida T; Shimizu K; Ushio Y; Hayakawa T; Kato A; Mogami H; Sakamoto Y
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2751-7. PubMed ID: 3463247
[TBL] [Abstract][Full Text] [Related]
8. [Studies on the mechanism of ACNU resistance in sublines of rat C6 glioma and 9L gliosarcoma in vitro].
Yoshida T; Shimizu K; Ushio Y; Hayakawa T; Kato A; Mogami H; Sakamoto Y
No Shinkei Geka; 1986 Oct; 14(11):1299-304. PubMed ID: 3468375
[TBL] [Abstract][Full Text] [Related]
9. [Anticancer drug induced sister chromatid exchange and correlation to cell survival in human brain tumor cells].
Aida T; Bodell WJ
No To Shinkei; 1987 Mar; 39(3):235-41. PubMed ID: 3472531
[TBL] [Abstract][Full Text] [Related]
10. [Development of ACNU-resistant meningeal gliomatosis models: establishment of resistant rat glioma subline against ACNU].
Yoshida T; Ushio Y; Hayakawa T; Yamada K; Kato A; Mogami H; Nakata Y
No Shinkei Geka; 1984 Aug; 12(9):1029-36. PubMed ID: 6594599
[TBL] [Abstract][Full Text] [Related]
11. [Combination therapy with HU IFN-beta and ACNU against malignant brain tumors, Part 1. Experimental study in vitro].
Yoshida J; Wakabayashi T; Inoue I; Kageyama N
Gan To Kagaku Ryoho; 1985 Jan; 12(1):99-104. PubMed ID: 3855355
[TBL] [Abstract][Full Text] [Related]
12. Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.
Saijo N; Ozaki A; Sakurai M; Ishihara J; Takahashi H; Sasaki Y; Hoshi A; Hamburger AW
Jpn J Cancer Res; 1986 May; 77(5):487-93. PubMed ID: 3089980
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
[TBL] [Abstract][Full Text] [Related]
14. [Overcoming of ACNU resistance in a subline of rat glioma in vitro and in vivo by reserpine].
Yoshida T; Shimizu K; Ushio Y; Hayakawa T; Mogami H; Sakamoto Y
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2141-6. PubMed ID: 3459396
[TBL] [Abstract][Full Text] [Related]
15. [Anti-tumor activity of ACNU against malignant glioma--a clinical application of in vitro sensitivity test of chemotherapeutic agent].
Shibuya N; Yoshida J; Kobayashi T; Kageyama N
No Shinkei Geka; 1983 Apr; 11(4):361-7. PubMed ID: 6306497
[TBL] [Abstract][Full Text] [Related]
16. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
17. In vitro sensitivity of nitrosourea-induced neurogenic tumors to ACNU.
Kida Y; Cravioto H; Hochwald G; Ransohoff J
Anticancer Res; 1982; 2(1-2):79-87. PubMed ID: 6956245
[TBL] [Abstract][Full Text] [Related]
18. Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells.
Wang P; Yu JP; Gao SY; An XM; Ren XB; Wang XG; Li WL
Cell Immunol; 2008; 253(1-2):59-65. PubMed ID: 18522858
[TBL] [Abstract][Full Text] [Related]
19. [Enhanced effect of reserpine on growth-inhibitory action of ACNU on ACNU resistance C6 glioma].
Yoshida T; Shimizu K; Ushio Y; Hayakawa T; Mogami H; Sakamoto Y
Gan To Kagaku Ryoho; 1984 Mar; 11(3):464-6. PubMed ID: 6584086
[TBL] [Abstract][Full Text] [Related]
20. [Overcoming of ACNU resistance in an ACNU-resistant subline of rat C6 glioma in vivo through enhanced effect of ACNU by calmodulin inhibitor].
Yoshida T; Shimizu K; Hayakawa T; Mogami H; Sakamoto Y; Egawa T
No Shinkei Geka; 1987 Mar; 15(3):261-7. PubMed ID: 3474542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
